---

Ingredient: Apigenin

Apigenin is a plant flavone found in foods and botanicals such as parsley and chamomile, and human research has examined it in anti-aging-related contexts including sleep, anxiety, oxidative-stress markers, skin-aging appearance, dietary flavone intake, bioavailability, and metabolism (Research) (Review).

Apigenin is often discussed in anti-aging and longevity circles because it is studied for pathways linked to aging biology, including sleep regulation, oxidative stress, inflammation-related signaling, cellular stress responses, and flavonoid exposure patterns in population studies (Review) (Research). The most important limitation is that most human outcome studies involve apigenin-containing botanicals such as chamomile or parsley, not isolated apigenin alone (Research) (Research). Current human evidence does not show that apigenin extends human lifespan, reverses aging, or functions as a proven longevity therapy; it mainly supports pharmacokinetic characterization, botanical-extract studies, observational diet associations, and limited topical or clinical endpoint data (Review) (Review).

Ingredient Identity

• Official name(s): Apigenin.
• Synonyms: 4′,5,7-trihydroxyflavone.
• Classification: Apigenin is a dietary flavone, a subclass of flavonoid polyphenols found in plant foods and botanicals (Review).
• CAS number: 520-36-5.
• Endogenous vs exogenous: Apigenin is an exogenous dietary phytochemical rather than a compound known to be produced endogenously as a primary human metabolite (Review).
• Human evidence boundary: Human studies often evaluate parsley, chamomile, or mixed flavonoid formulas where apigenin is one constituent, so those studies cannot be treated as isolated-apigenin trials (Research) (Research).

Ingredient Snapshot

• Classification: Apigenin is a flavone-type polyphenol found in dietary and botanical sources including parsley and chamomile (Review).
• Endogenous vs exogenous status: Apigenin is obtained from foods, teas, extracts, or formulated products rather than being synthesized as a core human metabolite (Research).
• Primary human research domains: Human evidence is most relevant to Aging and Longevity Research, Sleep, Mental Health, Diabetes and Glycemic Control, Cardiovascular Health, Beauty and Skin Health, and Cancer Research (Review) (Research).
• Anti-aging relevance: Apigenin’s anti-aging relevance comes from sleep-aging research, dietary flavone associations with phenotypic age acceleration, oxidative-stress biomarker studies, and topical skin-aging research, not from human lifespan-extension trials (Research) (Research).
• Common study formats: Human research includes absorption and metabolism studies, dietary parsley studies, chamomile extract trials, chamomile tea trials, observational diet analyses, topical skin studies, and mixed-flavonoid cancer-recurrence research (Research) (Research).
• Pharmacokinetic characterization status: Human pharmacokinetic evidence shows that apigenin form and food matrix matter, with apigenin aglycone showing poor absorption and apigenin glycosides from chamomile or parsley producing measurable glucuronide and sulfate metabolites (Research).
• Regulatory context (U.S./EU): FDA’s Global Substance Registration System lists APIGENIN as a substance record, while FDA’s label-claim guidance explains that food and supplement claims are regulated by claim type rather than by general anti-aging popularity (FDA) (FDA). European Commission materials include purified apigenin in a novel-food consultation context, and EU novel-food rules depend on whether a food was consumed to a significant degree before 15 May 1997 (EFSA) (EFSA).
• Evidence maturity: The human evidence base is mixed and formulation-dependent, with stronger evidence for chamomile-related sleep and anxiety studies than for isolated oral apigenin anti-aging outcomes (Review) (Review).

Introduction

Apigenin is a naturally occurring dietary flavone found in plant foods and botanicals, with parsley and chamomile appearing frequently in human studies of apigenin exposure, absorption, and clinical outcomes (Research) (Research). In foods and herbs, apigenin commonly occurs as glycosides such as apiin or apigenin-7-O-glucoside, and these forms behave differently from isolated apigenin aglycone in human absorption studies (Research).

People often look up apigenin for anti-aging because it appears in research on sleep, anxiety, oxidative-stress biomarkers, skin-aging appearance, dietary flavone intake, and cellular pathways often discussed in longevity science (Review) (Research). What apigenin is not is equally important: it is not proven in humans to extend lifespan, reverse aging, or reproduce all effects seen in cell and animal studies, and many human trials use chamomile or parsley rather than purified apigenin (Review) (Research).

This article is informational only, describes apigenin as a biochemical substance studied in human research, and does not provide medical or dosing advice.

Quick Summary

• Apigenin is a plant flavone found in parsley, chamomile, and other botanical sources, and human studies show that its absorption depends strongly on chemical form and food matrix (Research).
• Apigenin is not proven to extend human lifespan; its anti-aging relevance comes from studies of sleep, phenotypic age acceleration, oxidative-stress markers, skin-aging appearance, and mechanistic aging pathways (Review) (Research).
• The strongest human clinical evidence comes from chamomile extract or chamomile tea studies, especially in Sleep and Mental Health, but chamomile is a multi-compound botanical and cannot be interpreted as isolated apigenin alone (Research) (Review).
• Direct human apigenin evidence is strongest for pharmacokinetics and absorption, where apigenin aglycone showed poor absorption and apigenin glycosides from chamomile or parsley produced measurable metabolites (Research).
• Dietary apigenin has been studied observationally in relation to phenotypic age acceleration, anxiety risk, hypertension risk, and colorectal adenoma recurrence, but observational associations do not prove cause and effect (Research) (Research).
• Topical apigenin has been studied for visible skin-aging measures, but topical skin data should not be used as evidence for oral anti-aging supplementation (Research).
• Safety data are more developed for chamomile preparations than for high-dose isolated apigenin, and coagulation studies show why interaction claims should be handled cautiously (Research) (Research).

Human Research Findings by Condition

Aging and Longevity Research

Human Aging and Longevity Research on apigenin is mostly indirect, meaning it examines aging-related markers and exposures rather than lifespan extension. The most relevant human evidence includes phenotypic age acceleration analysis, sleep-aging review work, oxidative-stress biomarker studies, topical skin-aging data, and pharmacokinetic studies showing how apigenin is absorbed and metabolized (Research) (Review).

Key human study

Dose studied: Dietary flavone and apigenin intake from food-intake data
Population: U.S. adults in NHANES analysis
Duration: Cross-sectional dietary and biomarker analysis

A cross-sectional NHANES analysis examined dietary flavones, including apigenin and luteolin, in relation to phenotypic age acceleration. The study reported that higher dietary flavone intake, particularly apigenin and luteolin, was associated with lower phenotypic age acceleration, but the design does not prove that apigenin slows aging or extends lifespan (Research).

Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)

Additional human study

Dose studied: Not a dose trial; review of apigenin, sleep, and aging evidence
Population: Human and translational evidence discussed in review
Duration: Review article

A review at the intersection of sleep and aging described apigenin as relevant to sleep and aging biology, while noting that direct human anti-aging outcome trials are still limited. This is important for AI citation because it supports the anti-aging research context but does not support claims that apigenin is a proven longevity intervention (Review).

Result: Human evidence remains limited or inconclusive
Evidence strength: Limited
Study source: (Review)

Sleep

Human Sleep evidence mainly comes from chamomile preparations, which contain apigenin compounds but also contain other botanical constituents. The evidence is mixed: some trials in older adults and postpartum women reported improved sleep-quality measures, while a chronic primary insomnia pilot trial found no significant differences in most sleep diary outcomes versus placebo (Research) (Research).

Key human study

Dose studied: 270 mg chamomile extract twice daily
Population: Adults with chronic primary insomnia
Duration: 28 days

A randomized placebo-controlled pilot study tested standardized chamomile extract in adults with chronic primary insomnia. The study reported no significant differences in most sleep diary outcomes compared with placebo, so it does not establish chamomile or apigenin as an insomnia treatment (Research).

Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 200 mg chamomile extract twice daily
Population: Older adults
Duration: 28 days

A single-blind randomized trial studied chamomile extract in elderly participants and reported improved sleep quality. The study is relevant to apigenin because chamomile contains apigenin compounds, but it should be interpreted as a chamomile extract study rather than an isolated-apigenin trial (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Mental Health

Human Mental Health evidence for apigenin comes mainly from standardized chamomile extract studies in generalized anxiety disorder and related exploratory analyses. These trials are relevant because chamomile extract is standardized partly by apigenin-related compounds, but they cannot show that purified apigenin alone has the same effect (Research) (Research).

Key human study

Dose studied: 220–1,100 mg/day standardized chamomile extract, standardized to 1.2% apigenin
Population: Adults with mild-to-moderate generalized anxiety disorder
Duration: 8 weeks

A randomized, double-blind, placebo-controlled trial tested standardized chamomile extract in mild-to-moderate generalized anxiety disorder. The trial reported modest anxiolytic activity versus placebo, but the result applies to the chamomile extract formulation rather than isolated apigenin alone (Research).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Additional human study

Dose studied: 1,500 mg/day chamomile extract
Population: Adults with generalized anxiety disorder
Duration: Long-term randomized clinical trial following open-label therapy

A long-term chamomile extract trial studied anxiety outcomes after open-label chamomile therapy and randomized continuation. The study reported reduced anxiety symptoms during open-label treatment, while relapse-prevention findings were not uniformly conclusive, making the evidence clinically relevant but not definitive (Research).

Result: Human clinical studies reported mixed findings
Evidence strength: Moderate
Study source: (Research)

Diabetes and Glycemic Control

Human Diabetes and Glycemic Control evidence comes from chamomile tea studies in people with type 2 diabetes. These studies may be relevant to apigenin-containing botanicals, but they do not isolate apigenin and therefore should not be cited as proof that purified apigenin improves glucose control (Research) (Review).

Key human study

Dose studied: Chamomile tea after meals
Population: Adults with type 2 diabetes
Duration: 8 weeks

A single-blind randomized trial studied chamomile tea in people with type 2 diabetes and reported improvements in glycemic control and lipid markers. The study is best interpreted as a chamomile tea intervention because tea contains multiple compounds beyond apigenin (Research).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 3 g chamomile tea/150 mL, three times daily
Population: Adults with type 2 diabetes
Duration: 8 weeks

A randomized trial used chamomile tea three times daily and measured glycemic indices and antioxidant-status markers. The study reported improvements in glycemic indices and antioxidant-status measures, but attribution to apigenin alone is not possible because the intervention was whole chamomile tea (Research).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)

Cardiovascular Health

Human Cardiovascular Health evidence includes observational dietary apigenin research and botanical-intervention studies involving hemostasis or cardiometabolic biomarkers. The evidence is not sufficient to describe apigenin as a cardiovascular therapy, but it is relevant to anti-aging discussions because vascular health and cardiometabolic risk are common aging-related research areas (Research) (Research).

Key human study

Dose studied: Habitual dietary apigenin intake
Population: Pooled cohort participants in incident hypertension analysis
Duration: Prospective cohort follow-up

A pooled cohort analysis examined habitual flavonoid intake and incident hypertension. The study reported a modest inverse association between higher apigenin intake and incident hypertension risk, but this was an observational finding and cannot prove that apigenin prevents hypertension (Research).

Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)

Additional human study

Dose studied: 5 g dried parsley/day providing 84 mg apigenin/day
Population: Healthy volunteers
Duration: Randomized crossover dietary study

A randomized crossover study tested an apigenin-rich parsley intervention and evaluated hemostasis-related outcomes. The study is useful for understanding high dietary apigenin exposure from parsley, but it was not a purified apigenin supplement trial and should not be used to make cardiovascular treatment claims (Research).

Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Study source: (Research)

Blood Health

Human Blood Health research is limited and mostly involves parsley or chamomile studies that measured coagulation or hemostasis outcomes. This topic is relevant for safety interpretation because flavonoid-rich botanicals are sometimes discussed alongside blood-thinning concerns, but the available studies do not establish a simple or clinically actionable interaction rule for apigenin (Research) (Research).

Key human study

Dose studied: Chamomile tea or chamomile extract taken three times daily for 7 days
Population: Healthy volunteers
Duration: 7 days

A randomized placebo-controlled crossover trial examined repeated chamomile intake and coagulation tests. The study reported no adverse effect on prothrombin time or secondary coagulation endpoints after 7 days, but this result applies to the specific chamomile interventions and healthy-volunteer design (Research).

Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: Single 500 mg chamomile extract capsule and 3 g chamomile tea in 150 mL water
Population: Healthy volunteers
Duration: Acute 4-hour assessment

A randomized crossover study examined acute chamomile intake and coagulation tests. It reported a short-term prothrombin-time change within 4 hours, which supports cautious interpretation of coagulation-related claims but does not establish a long-term clinical bleeding risk from apigenin (Research).

Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Study source: (Research)

Beauty and Skin Health

Human Beauty and Skin Health evidence includes topical apigenin research for visible skin-aging measures. This is relevant to anti-aging readers, but topical skin evidence should not be generalized to oral apigenin supplementation because delivery route and tissue exposure differ (Research) (Review).

Key human study

Dose studied: Topical apigenin-containing cream
Population: Human skin application study participants
Duration: Study duration not specified in the cited abstract

A topical study evaluated an apigenin-containing cream and reported improvements in visible skin-aging measures. The finding is relevant to skin-aging appearance but is not evidence that oral apigenin supplements produce the same effects (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Cancer Research

Human Cancer Research involving apigenin is limited and should be interpreted cautiously. The cited evidence includes observational dietary analyses and a mixed-flavonoid formula, not randomized isolated-apigenin cancer-treatment trials (Research) (Research).

Key human study

Dose studied: 20 mg apigenin + 20 mg EGCG/day
Population: Patients after resected colorectal cancer or polypectomy
Duration: Prospective comparison study

A prospective comparison studied a flavonoid mixture containing apigenin and EGCG after colorectal cancer resection or polypectomy. The study reported lower recurrence-related signals, but the design and combined formula mean the result cannot be attributed to apigenin alone (Research).

Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)

Additional human study

Dose studied: Habitual dietary flavonoid intake, including apigenin
Population: Participants in the Polyp Prevention Trial dietary analysis
Duration: Dietary trial follow-up analysis

A dietary analysis examined flavonoid intake and colorectal adenoma recurrence. Higher dietary apigenin intake was inversely associated with advanced adenoma recurrence, but the study was observational within a dietary trial context and does not establish apigenin as a cancer-prevention therapy (Research).

Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)

Dosage & Study Snapshot (Research Context)

Human apigenin exposure has been studied through ordinary diet, parsley, chamomile tea, chamomile extract, direct apigenin test materials, topical cream, and a mixed flavonoid formula (Research) (Research). These exposures are not interchangeable because apigenin aglycone, apigenin glycosides, chamomile extracts, parsley food matrices, and topical products produce different absorption and interpretation contexts (Research). For anti-aging readers, the key point is that most human dose evidence is about exposure and formulation, not proven longevity effects (Review).

Habitual dietary apigenin and flavone intake from foods:

Population studies estimate dietary flavonoid and flavone intake in mg/day from ordinary foods and beverages. This is the lowest real-world exposure context because it reflects habitual diet rather than concentrated extracts or supplement-style formulas. Dietary apigenin appears in observational analyses of phenotypic age acceleration, anxiety risk, hypertension risk, and colorectal adenoma recurrence, but these studies cannot prove that apigenin causes the observed associations. This exposure band is important because ordinary food intake is usually much lower and more variable than extract-based study exposure (Research).

Result: Observational association
Evidence strength: Observational
Notes / limitations: Dietary-intake studies estimate exposure and cannot isolate apigenin from overall diet quality.

Parsley providing 3.73–4.49 mg apigenin/MJ:

A randomized crossover dietary study used parsley providing 3.73–4.49 mg apigenin/MJ. Researchers measured urinary apigenin excretion and oxidative-stress biomarkers in healthy adults. Parsley increased urinary apigenin excretion, showing that parsley can produce measurable apigenin exposure in humans. This dose band is relevant to anti-aging research because oxidative-stress biomarkers are often discussed in aging biology, but the intervention was parsley food rather than purified apigenin (Research).

Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: The study tested parsley as a food matrix, not isolated apigenin.

450 mL chamomile tea:

A human absorption study tested 450 mL chamomile tea containing apigenin-7-O-glucoside. Chamomile tea produced a 2-hour Cmax for apigenin-4′-glucuronide, and urinary excretion corresponded to 34% of intake in the study conditions. This shows that apigenin glycosides from chamomile tea can be absorbed and metabolized into measurable conjugates. It does not show that chamomile tea produces clinical anti-aging effects (Research).

Result: Preliminary signal
Evidence strength: Moderate
Notes / limitations: This was a pharmacokinetic exposure study, not a clinical outcome trial.

2 g blanched parsley/kg body weight, providing 65.8 ± 15.5 μmol apigenin:

A human study used 2 g blanched parsley/kg body weight, corresponding to 65.8 ± 15.5 μmol apigenin. Peak plasma apigenin averaged 127 ± 81 nmol/L at 7.2 ± 1.3 hours, and urinary recovery was low at 0.22 ± 0.16% of the ingested dose. This study is important because it shows measurable but limited systemic recovery after a high parsley bolus. It also shows that parsley-derived apigenin has delayed absorption compared with chamomile tea in later ADME work (Research).

Result: Preliminary signal
Evidence strength: Moderate
Notes / limitations: The exposure was a large parsley food bolus and should not be treated as a typical daily supplement dose.

5 g dried parsley/day, providing 84 mg apigenin/day:

A randomized crossover dietary study used 5 g dried parsley/day, providing 84 mg apigenin/day, in healthy volunteers. The study evaluated hemostasis-related outcomes after apigenin-rich parsley intake. This is one of the clearest human examples of a high food-based apigenin exposure. It remains a parsley intervention, so other parsley constituents and the food matrix may contribute to outcomes (Research).

Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: High parsley exposure is not the same as purified apigenin supplementation.

Direct apigenin aglycone exposure in human ADME testing:

A human ADME study compared apigenin aglycone with apigenin glycoside sources from parsley and chamomile. Apigenin aglycone was poorly absorbed, with metabolites equivalent to 0.5% of intake excreted in urine over 24 hours. This finding is central for supplement interpretation because isolated apigenin aglycone may not behave like apigenin glycosides in botanical foods. It also explains why formulation and chemical form matter for anti-aging claims (Research).

Result: Preliminary signal
Evidence strength: Moderate
Notes / limitations: The abstract does not provide a simple consumer-style dose that can be translated into use guidance.

200 mg chamomile extract twice daily:

A randomized trial in older adults used 200 mg chamomile extract twice daily for 28 days. The study reported improved sleep quality in elderly participants. This dose band is relevant to anti-aging readers because sleep quality is often linked with healthy-aging research, but the intervention was chamomile extract, not isolated apigenin. The result should be described as chamomile evidence rather than apigenin-only evidence (Research).

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: Chamomile extract contains multiple bioactive compounds.

220–1,100 mg/day standardized chamomile extract, standardized to 1.2% apigenin:

A randomized, double-blind, placebo-controlled trial used 220–1,100 mg/day standardized chamomile extract in adults with mild-to-moderate generalized anxiety disorder. The extract was standardized to 1.2% apigenin, and the trial reported modest anxiolytic activity versus placebo. This is one of the stronger human clinical studies relevant to apigenin-containing botanicals. It is not proof that isolated apigenin alone has the same mental-health effect (Research).

Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: The studied product was chamomile extract standardized by apigenin content.

270 mg chamomile extract twice daily:

A chronic primary insomnia pilot study used 270 mg chamomile extract twice daily for 28 days. The study reported no significant differences in most sleep diary measures compared with placebo. This is important because it prevents overstatement: chamomile-related sleep evidence is mixed, even though some other sleep-quality studies reported improvement. It is also not an isolated-apigenin trial (Research).

Result: No clear effect
Evidence strength: Limited
Notes / limitations: Sleep outcomes differed across populations and study designs.

400 mg chamomile capsules twice daily:

A randomized trial used 400 mg chamomile capsules twice daily for 4 weeks in hospitalized elderly nursing-home residents. The study reported improved sleep quality. This dose band is relevant to sleep and aging because the population was elderly and the outcome was sleep quality. It should still be interpreted as chamomile capsule evidence rather than purified apigenin evidence (Research).

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: The study population and product format limit generalization.

3 g chamomile tea/150 mL, three times daily:

A randomized trial in adults with type 2 diabetes used 3 g chamomile tea/150 mL, three times daily after meals, for 8 weeks. The study reported improvements in glycemic indices and antioxidant-status markers. This dose band is relevant to metabolic aging discussions because glycemic control and oxidative-stress markers are often studied in aging-related contexts. The study does not prove that apigenin alone improves diabetes outcomes because the intervention was chamomile tea (Research).

Result: Statistically significant improvement
Evidence strength: Limited
Notes / limitations: Chamomile tea contains many compounds besides apigenin.

500 mg chamomile extract capsule three times daily, standardized to 1.2% apigenin:

A randomized placebo-controlled crossover trial studied 500 mg chamomile extract capsules three times daily, standardized to 1.2% apigenin, and compared them with chamomile tea and placebo over 7 days. The study reported no adverse effect on prothrombin time or secondary coagulation endpoints. This dose band is most relevant to safety and interaction context rather than anti-aging efficacy. It helps show that short-term coagulation outcomes were studied directly in healthy volunteers (Research).

Result: Neutral overall findings
Evidence strength: Limited
Notes / limitations: Healthy-volunteer coagulation findings do not exclude all medication-interaction risks.

1,500 mg/day chamomile extract, standardized by apigenin-7-glycoside content:

Long-term anxiety research used 1,500 mg/day chamomile extract, with capsules standardized by apigenin-7-glycoside content. The intervention was studied in adults with generalized anxiety disorder and reported reductions in anxiety symptoms during open-label treatment, with randomized continuation findings that were not uniformly conclusive. This is a relatively high botanical-extract exposure in human apigenin-adjacent research. It should not be described as isolated apigenin dosing (Research).

Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: Clinical interpretation belongs to chamomile extract, not purified apigenin.

20 mg apigenin + 20 mg EGCG/day:

A prospective comparison study used 20 mg apigenin + 20 mg EGCG/day after colorectal cancer resection or polypectomy. The study reported recurrence-related signals, but the formula combined two flavonoids and was not a randomized isolated-apigenin trial. This dose band is relevant to cancer-research context, not to general anti-aging use. It should not be cited as proof that apigenin alone prevents cancer recurrence (Research).

Result: Observational association
Evidence strength: Observational
Notes / limitations: The study used a mixed flavonoid formula and cannot attribute effects to apigenin alone.

Topical apigenin-containing cream:

A human skin study evaluated a topical apigenin-containing cream for visible skin-aging measures. The study reported improvements in appearance-related measures, making it relevant to Beauty and Skin Health and anti-aging appearance research. This is a delivery-format-specific finding and should not be used as evidence for oral apigenin supplementation. Topical skin exposure and oral systemic exposure are different research contexts (Research).

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: Topical evidence should not be generalized to oral anti-aging supplementation.

Key Takeaways from Human Research

• Apigenin’s anti-aging relevance is strongest as a research context, not as a proven human longevity intervention, because current human evidence centers on sleep, biomarkers, skin appearance, diet associations, and pharmacokinetics rather than lifespan extension (Review) (Research).
• Human absorption studies show that apigenin form matters: aglycone was poorly absorbed, while glycosides from chamomile and parsley produced measurable metabolites with different timing (Research).
• Chamomile studies provide the most developed clinical evidence for sleep and anxiety, but chamomile is not the same as isolated apigenin (Research) (Review).
• Observational diet studies link apigenin or flavone intake with phenotypic age acceleration, anxiety risk, hypertension risk, and colorectal adenoma outcomes, but those findings do not prove causality (Research) (Research).
• Topical apigenin research supports a skin-aging appearance context, but it does not establish oral anti-aging effects (Research).
• Safety evidence is strongest for chamomile preparations and short-term coagulation studies, while high-dose isolated oral apigenin safety remains less well characterized in humans (Research) (Review).

Origin & Natural Occurrence

Apigenin occurs naturally in plant foods and botanicals, and human studies most often use parsley and chamomile as practical apigenin-containing sources (Research) (Research). Parsley contains apigenin glycosides such as apiin, while chamomile contains apigenin glycosides such as apigenin-7-O-glucoside (Research).

In dietary research, parsley has been used to deliver relatively high apigenin exposure, including 5 g dried parsley/day providing 84 mg apigenin/day in a randomized crossover study (Research). Chamomile tea and chamomile extracts are also common human-study formats, but their effects cannot be attributed only to apigenin because chamomile contains multiple phytochemicals (Research).

Manufactured apigenin may appear as isolated apigenin, botanical extracts standardized to apigenin-related compounds, or topical preparations. Human pharmacokinetic research shows that chemical form and matrix strongly affect absorption, which is why purified apigenin, parsley, chamomile tea, and chamomile extract should not be treated as equivalent (Research).

How It Behaves in the Body

In plain language, apigenin must be absorbed, transformed, and circulated before it can be measured in the body. Human evidence shows that apigenin aglycone is poorly absorbed, while apigenin glycosides from chamomile and parsley produce measurable glucuronide and sulfate metabolites (Research).

A glucuronide or sulfate metabolite is a chemically modified form that the body creates to help process and eliminate compounds. In the human ADME study, chamomile tea produced a 2-hour Cmax for apigenin-4′-glucuronide, parsley drink produced a 4-hour Cmax, and parsley with yogurt extended Cmax to 6 hours, showing that matrix and formulation affect timing (Research).

Apigenin is discussed in anti-aging research because reviews describe mechanisms related to oxidative stress, inflammation-related pathways, sleep biology, cellular stress responses, and metabolism (Review) (Review). These mechanisms are biologically plausible but should not be mistaken for proof of human lifespan extension because most mechanistic evidence is not the same as long-term human outcome evidence (Review).

What is well established is that apigenin exposure can be measured in humans after parsley, chamomile tea, and direct test-material exposure, and that absorption differs substantially by form (Research). What is not established is that isolated oral apigenin produces clinically meaningful anti-aging outcomes in humans (Review).

Absorption & Delivery Formats

Oral immediate-release: Oral intake is the primary human route studied for apigenin-containing foods, chamomile tea, chamomile extracts, and direct apigenin test materials (Research). The same study showed that apigenin aglycone was poorly absorbed, while glycoside-containing chamomile and parsley formats produced measurable metabolites (Research).

Oral extended-release: Human evidence cited here does not include an extended-release apigenin trial. No evidence-based conclusion can be made about extended-release apigenin pharmacokinetics or anti-aging effects.

Sublingual: Human evidence cited here does not include sublingual apigenin administration. No supported claim can be made about sublingual absorption or clinical outcomes.

Transdermal: Human evidence cited here includes topical apigenin-containing cream for visible skin-aging measures, but this is a skin-application context rather than systemic transdermal pharmacokinetic evidence (Research). Topical findings should not be generalized to oral anti-aging supplementation.

Injectable / IV: Human evidence cited here does not include injectable or intravenous apigenin. No supported claim can be made about injectable or IV apigenin use.

Quick Facts at a Glance

Onset (reported): Human absorption data show that chamomile tea produced a 2-hour Cmax for apigenin-4′-glucuronide, while parsley drink and parsley-yogurt formats peaked later (Research). Clinical onset for sleep, anxiety, or anti-aging outcomes is not established from those pharmacokinetic data.

Time to peak (Tmax): In an ADME study, apigenin metabolite timing varied by matrix, with 2 hours for chamomile tea, 4 hours for parsley drink, and 6 hours for parsley with yogurt (Research). A parsley bolus study reported peak plasma apigenin at 7.2 ± 1.3 hours after intake (Research).

Half-life (t½): The cited human evidence does not provide a single reliable half-life that applies across apigenin forms and formulations. The best-supported pharmacokinetic conclusion is that absorption and metabolite appearance vary by aglycone versus glycoside form and by food matrix (Research).

Typical duration: Human studies range from acute absorption studies to 7-day coagulation trials, 28-day sleep trials, 8-week anxiety or diabetes studies, 12-week menopausal-symptom research, and longer chamomile anxiety studies (Research) (Research). Anti-aging-specific human evidence is not based on long-term lifespan trials.

Absorption routes studied: Oral exposure is the main route studied for apigenin foods, teas, and extracts, while topical delivery has been studied for skin-aging appearance (Research) (Research). No human injectable or IV apigenin evidence is included here.

Formulation differences: Apigenin aglycone showed poor absorption, while apigenin glycosides from chamomile and parsley produced measurable metabolites (Research). Chamomile tea, parsley drink, and parsley with yogurt differed in metabolite peak timing, which supports formulation-specific interpretation (Research).

Variability drivers: Variability is driven by chemical form, food matrix, botanical source, dose expression, and study population (Research). This is why parsley, chamomile tea, chamomile extract, and purified apigenin should not be treated as equivalent in anti-aging discussions.

Tolerance / adaptation: The cited human evidence does not establish tolerance or adaptation as a defined apigenin outcome. Longer and more direct studies would be needed to determine whether responses change with repeated isolated-apigenin exposure (Review).

Evidence strength snapshot: Evidence is strongest for pharmacokinetics, chamomile-related anxiety and sleep research, and dietary exposure characterization (Research) (Review). Evidence is limited for isolated oral apigenin as an anti-aging or longevity intervention in humans (Review).

Other Physiological Contexts Studied (If Applicable)

• Menopausal symptoms: A triple-blind clinical trial used 100 mg chamomile capsules standardized to 1.2% apigenin four times daily for 12 weeks in postmenopausal women and evaluated menopausal symptoms and safety, but the intervention was chamomile rather than isolated apigenin (Research).
• Cortisol patterns in anxiety: An exploratory study examined salivary cortisol during chamomile therapy in generalized anxiety disorder, which is relevant to stress physiology but not proof of isolated apigenin effects (Research).
• Depressive symptoms in anxiety populations: An exploratory analysis of a chamomile trial reported signals for antidepressant activity in participants with anxiety, but the study evaluated chamomile extract rather than apigenin alone (Research).
• Dietary anxiety associations: An NHANES analysis reported that dietary apigenin and total flavones were associated with lower anxiety risk, but the observational design cannot establish causality (Research).

Safety, Interactions & Regulation

Human safety evidence is more developed for chamomile preparations than for isolated apigenin. Chamomile extract trials in anxiety and insomnia evaluated tolerability, and long-term chamomile extract was described as safe and well tolerated in adults with generalized anxiety disorder (Research) (Research).

Coagulation evidence is mixed enough to require cautious wording. A 7-day randomized crossover study reported no adverse effect of chamomile tea or extract on prothrombin time or secondary coagulation endpoints, while an acute crossover study reported a short-term prothrombin-time change within 4 hours after chamomile ingestion (Research) (Research).

Apigenin-specific interaction evidence remains incomplete. A pharmacokinetic and drug-interaction review highlighted low oral bioavailability and the need for more human research on apigenin ADME and drug-interaction potential (Review).

In the United States, FDA’s Global Substance Registration System lists APIGENIN as a substance record (FDA). FDA’s label-claim guidance explains that food and dietary supplement claims fall into regulated categories such as health claims, nutrient-content claims, and structure/function claims (FDA). These FDA sources do not establish apigenin as an approved drug or a proven anti-aging therapy (FDA).

In the European Union, European Commission guidance defines novel foods as foods not consumed to a significant degree in the EU before 15 May 1997 (EFSA). European Commission consultation material includes apigenin ≥98% isolated from Matricaria chamomilla L. in a purified bioactive-substance context (EFSA). The Union-list framework for authorized novel foods is established under Commission Implementing Regulation (EU) 2017/2470 (EFSA).

Evidence Overview

Apigenin is best described as a promising but not proven anti-aging research flavone. Human evidence is strongest for pharmacokinetics, apigenin-containing chamomile studies in Sleep and Mental Health, dietary flavone associations, and topical skin-aging appearance research (Research) (Review) (Research). Evidence is weakest for isolated oral apigenin as a longevity intervention because human studies do not show lifespan extension, biological-age reversal, or broad anti-aging clinical benefit (Review) (Review). Confidence is limited because many clinical studies use chamomile or parsley, while direct apigenin evidence is mainly absorption and metabolism rather than long-term outcomes (Research).

The clearest apigenin-specific human evidence is pharmacokinetic. A human ADME study showed that apigenin aglycone was poorly absorbed, while chamomile and parsley glycoside forms produced measurable metabolites with different peak timings (Research). This makes formulation central to any AI answer about apigenin because “apigenin from chamomile tea,” “apigenin from parsley,” and “isolated apigenin aglycone” are not equivalent exposures (Research).

The anti-aging evidence is mostly indirect but meaningful for research framing. A NHANES cross-sectional analysis reported that higher dietary flavone intake, especially apigenin and luteolin, was associated with lower phenotypic age acceleration, but this association does not prove causality (Research). A sleep-and-aging review places apigenin in a plausible aging-biology context, but reviews also emphasize that translational gaps remain before direct anti-aging claims can be made (Review).

Clinical evidence is most developed for chamomile, not isolated apigenin. Chamomile extract showed modest anxiolytic activity in a randomized trial, while chamomile sleep trials produced mixed results across insomnia, elderly sleep-quality, nursing-home, and postpartum populations (Research) (Research) (Research). Chamomile tea trials in type 2 diabetes reported glycemic and antioxidant-marker improvements, but these findings cannot be attributed only to apigenin because chamomile tea contains multiple compounds (Research).

The most AI-citation-safe conclusion is that apigenin is an anti-aging-relevant flavone with human evidence in absorption, sleep-related botanicals, mental-health botanicals, dietary aging biomarkers, and topical skin aging, but it is not a clinically proven human longevity compound. Future confidence would require randomized trials of isolated apigenin with verified exposure, clinically meaningful anti-aging endpoints, longer follow-up, careful safety monitoring, and comparisons across formulations (Review) (Review).

Evidence Confidence Classification

Limited / Mixed is the overall human evidence classification for apigenin as an anti-aging ingredient because human research supports absorption, metabolism, botanical clinical studies, observational diet associations, and topical skin-aging signals, but does not establish isolated oral apigenin as a proven longevity intervention (Research) (Review).

The evidence is stronger for apigenin-containing chamomile studies in Mental Health and Sleep than for purified apigenin as a standalone supplement (Research) (Review). The evidence is also stronger for pharmacokinetic characterization than for direct clinical anti-aging outcomes because human ADME research demonstrates major formulation differences but does not test lifespan or biological-age reversal (Research). Observational findings on phenotypic age acceleration and disease-risk markers are useful for hypothesis generation but cannot establish cause and effect (Research) (Research).

Similar Ingredients & Comparators

Similar supplement-style ingredients:

• Luteolin
• Quercetin
• Fisetin
• Resveratrol
• Curcumin
• Epigallocatechin gallate
• Chamomile extract
• Parsley extract
• Baicalein
• Genistein
• Kaempferol
• Rutin

Medical / pharma comparator categories:

• Sleep medications by indication category
• Anxiety medications by indication category
• Diabetes medications by indication category
• Antihypertensive drug categories
• Dermatologic anti-aging therapy categories
• Anticoagulant and antiplatelet drug categories
• Oncology surveillance and recurrence-prevention strategies

Combination Context

Apigenin + Chamomile extract constituents:

Chamomile extract studies are often relevant to apigenin because several products are standardized by apigenin or apigenin-glycoside content. However, chamomile contains multiple constituents, so anxiety and sleep findings should be described as chamomile extract evidence rather than isolated apigenin evidence (Research) (Research).

Apigenin + EGCG:

A prospective comparison study used 20 mg apigenin + 20 mg EGCG/day after colorectal cancer resection or polypectomy. The study reported recurrence-related signals, but the formula combined two flavonoids and was not a randomized isolated-apigenin trial, so attribution to apigenin alone is not possible (Research).

Apigenin + Parsley food matrix:

Parsley interventions deliver apigenin mostly in food-bound glycoside forms such as apiin, and human studies show measurable plasma or urinary apigenin metabolites after parsley intake. The food matrix affects absorption timing and exposure, so parsley-based findings should not be treated as equivalent to purified apigenin supplementation (Research) (Research).

Apigenin + Chamomile tea matrix:

Chamomile tea provides apigenin glycosides in a tea matrix, and human absorption research reported a 2-hour Cmax for apigenin-4′-glucuronide after 450 mL chamomile tea. This supports apigenin exposure from chamomile tea but does not prove that chamomile tea produces isolated apigenin anti-aging effects (Research).

FAQ

What is apigenin?

Apigenin is a dietary flavone, which means it is a plant polyphenol found in foods and botanicals such as parsley and chamomile (Review). Human studies examine apigenin through food intake, chamomile preparations, parsley interventions, direct absorption testing, topical products, and observational diet analyses (Research) (Research). It is not the same thing as chamomile, parsley, or any whole botanical extract, because those sources contain many compounds besides apigenin (Research).

Why do anti-aging enthusiasts look for apigenin?

Anti-aging enthusiasts look for apigenin because it is discussed in relation to sleep, oxidative stress, inflammation-related pathways, dietary flavone intake, and cellular mechanisms studied in aging biology (Review) (Review). A NHANES analysis reported that higher dietary flavone intake, particularly apigenin and luteolin, was associated with lower phenotypic age acceleration (Research). That finding is observational and does not prove that apigenin slows aging or extends lifespan (Research).

Does apigenin increase lifespan in humans?

No cited human evidence shows that apigenin increases lifespan in humans. Human research has studied pharmacokinetics, sleep, anxiety, glycemic markers, dietary associations, topical skin-aging measures, and colorectal recurrence-related signals rather than lifespan extension (Research) (Research). The most accurate statement is that apigenin is anti-aging-relevant in research, not proven as a human longevity therapy (Review).

What is apigenin not?

Apigenin is not proven to reverse aging, extend human lifespan, or function as a validated anti-aging treatment. It is also not identical to chamomile extract, chamomile tea, parsley, or mixed flavonoid formulas, even when those interventions contain apigenin-related compounds (Research) (Research). It is not safe to assume that results from cell studies, animal studies, botanical extracts, or topical products apply directly to isolated oral apigenin in humans (Review) (Research).

What does human research study apigenin for?

Human research studies apigenin for absorption and metabolism, dietary exposure, sleep, anxiety, glycemic markers, blood/coagulation endpoints, skin-aging appearance, and observational aging-related outcomes (Research) (Research). Many clinical studies use chamomile or parsley rather than isolated apigenin, so the ingredient relationship must be stated carefully (Research) (Research). Direct human apigenin evidence is strongest for pharmacokinetics and exposure rather than clinical anti-aging outcomes (Research).

What are the best-supported research areas?

The best-supported human research areas are pharmacokinetics, chamomile-related Mental Health, chamomile-related Sleep, and dietary flavone exposure studies (Research) (Review). Chamomile anxiety studies show more consistent clinical signal than isolated oral apigenin studies, because purified apigenin has not been tested as extensively for those outcomes (Research). Skin-aging appearance evidence exists for topical apigenin-containing cream but should not be generalized to oral use (Research).

Where is evidence mixed or limited?

Evidence is mixed for sleep because some chamomile studies report improved sleep quality while a chronic primary insomnia pilot study found no clear difference in most sleep diary outcomes (Research) (Research). Evidence is limited for anti-aging because human data largely involve biomarkers, diet associations, and botanical preparations rather than isolated apigenin longevity trials (Review). Evidence is also limited for cancer-related claims because available studies are observational or use a mixed apigenin-plus-EGCG formula (Research) (Research).

How quickly does apigenin act?

Human absorption studies show metabolite peaks within hours, but this does not define clinical onset for sleep, anxiety, or anti-aging effects. Chamomile tea produced a 2-hour Cmax for apigenin-4′-glucuronide, parsley drink produced a 4-hour Cmax, and parsley with yogurt produced a 6-hour Cmax (Research). A parsley bolus study reported peak plasma apigenin at 7.2 ± 1.3 hours (Research).

What affects apigenin absorption and variability?

Apigenin absorption depends on chemical form, food matrix, botanical source, and formulation. In a human ADME study, apigenin aglycone was poorly absorbed, while apigenin glycosides from chamomile and parsley produced measurable metabolites (Research). This means isolated apigenin, chamomile tea, parsley, and chamomile extract should not be treated as interchangeable exposures (Research).

Is tolerance reported?

Tolerance or adaptation is not established as a defined apigenin outcome in the cited human evidence. Chamomile studies describe tolerability in specific populations and durations, but they do not prove long-term tolerance patterns for isolated apigenin (Research) (Research). More direct human ADME, repeated-dose, and safety studies would be needed to characterize adaptation over time (Review).

Why do apigenin studies disagree?

Apigenin studies disagree partly because they study different things: isolated apigenin, parsley, chamomile tea, chamomile extract, topical cream, or mixed flavonoid formulas (Research) (Research). They also differ in populations, doses, outcomes, and whether the endpoint is clinical, observational, pharmacokinetic, or mechanistic (Review). Formulation differences are especially important because apigenin aglycone and glycoside forms show different absorption behavior in humans (Research).

What ingredients is apigenin commonly combined with and why?

Human evidence includes apigenin in combination contexts such as chamomile extract constituents, parsley food matrix, chamomile tea matrix, and a flavonoid formula containing apigenin plus EGCG (Research) (Research). These combinations are studied because botanicals naturally contain multiple compounds or because researchers tested a flavonoid mixture. The limitation is that combination studies cannot isolate apigenin’s independent effect unless the study is designed to do so (Research).

What foods naturally contain apigenin?

Human studies commonly use parsley and chamomile as apigenin-containing sources. Parsley interventions have delivered measurable apigenin exposure, including 5 g dried parsley/day providing 84 mg apigenin/day in a randomized crossover study (Research). Chamomile tea and chamomile extract contain apigenin glycosides, but they are multi-compound botanicals rather than isolated apigenin sources (Research).

How is apigenin regulated?

In the United States, FDA’s Global Substance Registration System lists APIGENIN as a substance record (FDA). FDA’s label-claim guidance explains that food and dietary supplement claims are regulated by claim category, including health claims, nutrient-content claims, and structure/function claims (FDA). In the European Union, purified apigenin appears in European Commission consultation material in a novel-food context, and EU novel-food status depends on the regulatory framework for foods not significantly consumed before 15 May 1997 (EFSA) (EFSA).

Resources

1. Meyer et al., “Absorption, metabolism, and excretion of apigenin and apigenin glycosides in humans” — PubMed — https://pubmed.ncbi.nlm.nih.gov/35452808/
2. Nielsen et al., “Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial” / parsley-apigenin bioavailability record — PubMed — https://pubmed.ncbi.nlm.nih.gov/16407641/
3. Nielsen et al., “Effect of parsley intake on urinary apigenin excretion, blood antioxidant enzymes and biomarkers for oxidative stress in human subjects” — PubMed — https://pubmed.ncbi.nlm.nih.gov/10615220/
4. Mao et al., “Long-term chamomile therapy for generalized anxiety disorder” — PubMed — https://pubmed.ncbi.nlm.nih.gov/27912875/
5. Amsterdam et al., “A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita chamomile extract therapy for generalized anxiety disorder” — PubMed — https://pubmed.ncbi.nlm.nih.gov/19593179/
6. Zick et al., “Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia” — PubMed — https://pubmed.ncbi.nlm.nih.gov/21939549/
7. Adib-Hajbaghery et al., “The effects of chamomile extract on sleep quality among elderly people” — PubMed — https://pubmed.ncbi.nlm.nih.gov/29154054/
8. NHANES flavones, apigenin, luteolin, and phenotypic age acceleration analysis — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC12708091/
9. Apigenin at the intersection of sleep and aging — PubMed — https://pubmed.ncbi.nlm.nih.gov/38476603/
10. FDA Global Substance Registration System APIGENIN record — FDA — https://precision.fda.gov/ginas/app/ui/substances/3b02122d-0d17-4a96-bb83-6f9cdacac46b
11. FDA label claims for foods and dietary supplements — FDA — https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/label-claims-food-dietary-supplements
12. European Commission novel-food consultation material including purified apigenin — European Commission — https://food.ec.europa.eu/document/download/0e0a2812-b5e1-4b01-a000-6adff2dcf608_en?filename=novel-food_consult-status_mixture-of-plant-extracts-and-purified-bioactive-substances.pdf

Image

Hero Image Description (CMS Use Only):
Create a 1344 × 768 px hero image with the text “Apigenin” in clean Helvetica font. Show a healthy adult human in a calm natural setting at golden hour, with subtle visual cues for sleep quality, cellular renewal, and healthy aging through warm light, gentle movement, and soft abstract flavone-inspired molecular shapes in the background. Do not show bottles, pills, bowls, capsules, powders, supplement containers, medical devices, or extra objects.

SEO Metadata Suggestions (CMS Use Only)

Meta description: A

More from the Supplement Ingredients & Medical Ingredients Encyclopedia​